Keyphrases
Immunogenicity
100%
Neutralizing Antibodies
100%
Pseudovirus
100%
Heterologous Boost
100%
SARS-CoV-2 Variants
100%
NVX-CoV2373
100%
Ad26
66%
COVID-19 Booster Vaccine
66%
Protein-based
33%
Immunogenic
33%
Safety Concerns
33%
Adenoviral
33%
Prototypic
33%
SARS-CoV-2 Infection
33%
Heterologous Protein
33%
Humoral Response
33%
Acceptable Alternatives
33%
Booster Dose
33%
Booster Vaccine
33%
MRNA Vaccine
33%
D614G
33%
BNT162b2
33%
BNT162b2 Vaccine
33%
MRNA-1273
33%
Heterologous Booster
33%
Omicron Sub-lineages
33%
Short-term Durability
33%
XBB.1
33%
BQ.1.1
33%
Immunology and Microbiology
Immunogenicity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Booster Dose
100%
Neutralizing Antibody
75%
Antibody Titer
50%
COVID-19
50%
Humoral Immunity
25%
Antibody Response
25%
Lineages
25%
Omicron Coronavirus Variant
25%
Infection
25%
Medicine and Dentistry
Immunogenicity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Booster Dose
100%
Neutralizing Antibody
75%
COVID-19
50%
Messenger RNA
50%
Infection
25%
Humoral Immunity
25%
Antibody Response
25%
mRNA Vaccine
25%
Omicron Coronavirus Variant
25%
Biochemistry, Genetics and Molecular Biology
SARS Coronavirus
100%
Immunogenicity
100%
Neutralizing Antibody
100%
Titer
66%
Messenger RNA
66%
Humoral Immunity
33%
Antibody Response
33%
mRNA Vaccine
33%
Omicron
33%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
100%
Neutralizing Antibody
100%
SARS Coronavirus
100%
Messenger RNA
66%
Infection
33%
mRNA Vaccine
33%